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Sllmmary 
CD6 is a 130-kD glycoprotein expressed on the surface of thymocytes and peripheral blood T 
cells that is involved in TCK-mediated T cell activation. In thymus, CD6 mediates interactions 
between thymocytes and thymic epithelial (TE) cells. In indirect immunofluorescence assays, a 
recombinant CD6-immunoglobulin fusion protein (CD6-Kg) bound to cultured human TE cells 
and to thymic fibroblasts. CD6-Rg binding to TF and TE cells was trypsin sensitive, and 54 
_+  4% of binding was divalent cation dependent. By screening the blind panel of 479 mono- 
clonal antibodies (mAbs) from the 5th International Workshop on Human Leukocyte Differenti- 
ation Antigens for expression on human TE cells and for the ability to block CD6-Rg binding 
to TE cells, we found one mAb 04-81) that significantly inhibited the binding of CD6-Kg to 
TE cells (60  _+  7% inhibition).  A second mAb to the surface antigen identified by mAb J4-81, 
J3-119, enhanced the binding of CD6-Kg to TE cells by 48 +  5%. Using covalent cross-linking 
and trypsin digestion, we found that mAb J4-81 and CD6-Kg both bound to the same 100-kD 
glycoprotein (CD6L100) on the surface of TE cells. These data demonstrate that a 100-kD glyco- 
protein on TE cells detected by mAb J4-81 is a ligand for CD6. 
I 
ntrathymic development of human T cells is regulated by 
the interactions between thymocytes and stromal cells of 
the thymic microenvironment (for a review see reference 1). 
Both epithelial and fibroblast components of thymic stroma 
are important for thymocyte  maturation (2). mAb-mediated 
inhibition of thymocyte-stromal  cell binding has shown that 
CD2,  CD54,  CD58,  LFA-1 (CDlla/CD18),  very late an- 
tigen 3 (VLA-3) (CD49c/CD29), VLA-4 (CD49d/CD29), 
VLA-6 (CD49f/CD29),  and fibronectin  serve as adhesion 
receptors for thymocyte-stromal cell interactions (3-7). Vollger 
et al. (3) screened for the ability of mAbs to inhibit thymic 
epithelial (TE) cell-thymocyte  binding and found that CD6 
mAbs partially inhibited TE-thymocyte  binding, suggesting 
that CD6 may also be involved in thymocyte-stromal  inter- 
actions. 
CD6 is a 130-kD glycoprotein that is differentially  expressed 
on the surface of mature human thymocytes, the majority 
of peripheral blood T cells, a subset of B cells, and neurons 
of the cerebral cortex (8-10). CD6 is a member of the mac- 
rophage scavenger  receptor protein family and is homologous 
to the CD5 molecule (11). The role of CD6 in T cell devel- 
opment has not been identifed. On peripheral blood T cells, 
CD6 is involved in T cell activation as CD6 mAb T12 can 
augment T cell proliferation in autologous mixed lympho- 
cyte reactions  (MLR)  (12). mAbs to  CD6  also augment 
TCR-mediated T cell activation (13-16), and CD6 is tyro- 
sine phosphorylated  after TCR-mediated T  cell triggering 
(17). Clinically, anti-CD6 mAbs (T12) have  been used to de- 
plete T cells  from bone marrow transplants and prevent GVHD 
(18). CD6  may be involved in  autoimmunity as  CD3 +, 
CD6-  T  cells that survive T12-ricin  treatment show de- 
creased aUoreactivity  compared with CD6 + T cells (19), and 
the anti-CD6 mAb UMCD6 inhibited the autoreactive re- 
sponse of cloned T  cells in autologous MLRs (20). 
In this study, we have used CD6-Ig fusion proteins and 
a panel of 479 mAbs to demonstrate that TE cells express 
a 100-kD divalent cation-independent ligand for CD6 that 
is recognized by mAbs J4-81 and J3-119. 
Materials and Methods 
Cells and Culture Conditions.  TE cells and thymic  fibrobhsts (TF) 
were  cultured  by an explant technique  as described  (21, 22). Human 
thymus tissue was obtained from the Department of Pathology, 
Duke University  Medical  Center, as discarded  tissue from children 
undergoing  corrective  cardiovascular  surgery,  and thymocytes  pre- 
pared as described (23). COS-M6 cells and HBbl00 ceils (Amer- 
ican Type  Culture Collection  [ATCC], Rockvilh, MD) were  grown 
in DMEM containing 10% FCS, 1 mM sodium pyruvate, 0.025 
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mAbs.  Antibodies  used in this study were: P3X63/Ag8 (control 
mAb; ATCC), A3D8 (anti-CD44; 24), J4-81, and J3-119 (25), and 
the blind panel of  479 mAbs from the 5th International Workshop 
on Human Leukocyte Differentiation Antigens (HLDA-V) (26). 
Detection of  Cell Su~ce Antigens.  Cells,  suspended  in either PBS 
or DMEM (with or without 10 mM EDTA) containing 2% BSA 
and 0.1% NAN3, were incubated with a recombinant CD6-Ig fu- 
sion protein (CD6-Rg) (27), CD5-Rg (28), or human IgG (Sigma 
Chemical Co., St. Louis, MO) (100 #g/ml) for 30 rain at 4~  and 
washed  with  PBS  containing  2%  BSA  and  0.1%  NAN3. 
Fluorescein-conjugated  goat anti-human IgG1 (Kirkegaard  & Perry 
Laboratories, Inc., Gaithersburg, MD) was used as a secondary  re- 
agent.  Cells were analyzed on  a  FACStar  Plu'|  flow cytometer 
(Becton Dickinson, & Co., Mountain View, CA). To determine 
trypsin sensitivity  of fusion protein interactions, cells were incubated 
with 0.2%  trypsin in PBS containing 1 mM EDTA for 30 rain 
at 37~  and washed before reactivity with fusion proteins. 
Screening of mAbs for  Inhibition of CD6-Rg Binding to  TE 
Cells.  mAbs  from the blind panel of the HLDA-V and a panel 
of anti-integrin mAbs were screened for reactivity to the surface 
of TE cells (29). Of the 154 mAbs that reacted with TE cells, 126 
were used in this assay. TE cells (10  s) were incubated with ascites 
or purified mAb (1:100) for 15 min at 4~  Either CD5-Rg or 
CD6-Rg (5 #g) were added and allowed to react for 2 h at 4~ 
washed, and, labeled  with a fluorescein-conjugated  antiserum  specific 
for the Fc portion of human IgG (Sigma Chemical Co.). To ac- 
count for any cross-reactivity  of fluorescein-conjugated  anti-human 
IgG with murine Ig, binding was determined as the difference  in 
fluorescence (AFL) between  samples containing  CD6-Rg  and 
CD5-Rg. 
Imrnunoprecipitation  and Protein Cross-linking  Conditions.  TE cells, 
surface labeled with 12sI as described (30), were incubated with 
mAbs (1:100 ascites), purified Ig (200/zg/ml),  or Ig fusion pro- 
teins (200 #g/ml) for 2 h in DME/5% FBS. After washing with 
cold PBS, bound Igs were cross-linked to cell surface  proteins with 
I mM 3,3' dithiobis(sulfo-succinimidyl  propionate) (DTSSP) (Pierce 
Chemical Co., Rockford, IL) in PBS for 60 min at 4~  After ad- 
dition of 20 mM Tris-HC1 (pH 8.0), the cells were washed with 
cold PBS. Cells were lysed in PBS containing 1% NP-40, 1 mM 
PMSF, 0.1 mM Nc~-p-Tosyl-r-lysine  chloromethyl ketone (TICK) 
and  0.1% NAN3.  Ig  complexes were purified with  protein 
A-Sepharose beads (Sigma Chemical Co.). Before  SDS-PAGE, pro- 
tein complexes  were solubilized  with SDS loading buffer (2% SDS, 
10 mM Tris-HCl, pH 7.4, 20% glycerol, bromphenol blue) con- 
taining 2% 2-ME. To confirm identity of proteins, purified pro- 
tein complexes were treated with 0.2%  trypsin in 1 mM EDTA 
for 30 min at  25~  (31) before solubilization and cross-linker 
cleavage. After SDS-PAGE, the gels were fixed, dried, and exposed 
to autoradiography film. 
Immunohistology.  Normal human tissues were obtained as dis- 
carded tissue from the Department of Pathology, Duke University 
Medical Center  and  frozen  in  liquid  nitrogen.  Indirect  im- 
munofluorescence (IF) assays of mAb  reactivity  on  acetone- 
fixed tissue sections were performed as described (32). 
Results 
CD6-Rg  Binding  to  Cells of the  Thymic  Microenviron- 
ment.  The ability of CD6-Rg fusion protein to bind to TE 
cells,  thymic fibroblasts,  and thymocytes was determined by 
indirect IF and flow cytometry. CD6-Rg bound to the sur- 
face of TE cells as well as to thymic fibroblasts,  but not to 
thymocytes (Fig. 1 A). Binding of CD6-Rg to TE cells was 
trypsin sensitive and partially dependent upon divalent cat- 
ions (Fig. 1 B). CD6-P,g bound well to TE cells in a buffer 
containing DME and 5% fetal bovine serum, but in the pres- 
ence of 10 mM EDTA, binding of CD6-R.g to TE cells was 
inhibited by 54  +  4%  (n  =  5, p  <0.001,  Fig.  1 B). 
Antibody-mediated  Inhibition  of CD6-Rg  Binding  to  TE 
Cells.  To begin to identify the CD6 ligand(s), a panel of 
479 mAbs from HLDA-V was screened for reactivity to the 
surface of TE cells by indirect IF and flow cytometry. Of 
the 154 mAbs that reacted with the surface of TE cells (29), 
126 mAbs were used in assays to inhibit the binding of CD6- 
Rg to TE cells. Of the 122 mAbs that did not react with 
the secondary antiserum, only one 04-81) inhibited the binding 
of CD6-Rg to TE cells, mAb J4-81  inhibited the binding 
of CD6-Rg  to TE cells by 60  +  7%  (n  =  10, p  <0.001) 
and to the breast cell line HBL-100 by 40  _+  3%  (n  =  3, 
p <0.02) (Table 1), which has also been shown to bind CD6- 
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Figure 1.  Thymic  epithdial calls 
and thymic fibroblasts express a 
trypsin-sensitive  surface  ligand for 
CD6.  (A)  Representative histo- 
grams depicting  the reactivities  with 
CD6-Rg of thymic  epithelial  cells, 
thymic  fibroblasts, and thymocytes. 
Also shown  in each panel are back- 
ground levels of fluorescence  with 
control fusion  protein  CD5-R.g. (B) 
The binding  of  CD6-Rg to TE cells 
in either  divalent  cation-containing 
media (-  EDTA), trypsin-treated 
TE cells in media (trypsin), or TE 
cells in  PBS  +  10  mM  EDTA 
(EDTA) was  tested. Shown are 
histograms of a representative ex- 
periment (from >10  performed) 
depicting CD6-R.g binding to TE 
cells as determined  by indirect  IF and 
flow cytometry. 
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HBL-IO0 Cells 
Percent  Percent 
Cell Type  mAb  A FL*  binding*  inhibitions 
TE cells  P3  52  100  0 
CD9  60  115  -  15 
CD24  48  92  8 
CD40  48  92  8 
CD46  57  110  -  10 
CD51  46  88  12 
CD54  44  85  15 
CD58  45  87  13 
CD59  52  100  0 
CD63  53  102  - 2 
CD66  56  108  - 8 
J4-81  21  40  60 
HBL-100  P3  58  100  0 
J4-81  34  59  41 
" AFL = Fluorescence  (CD6-Rg)-  fluorescence  (CD5-Rg). Shown  is 
the binding  of CD6-Rg compared  with control (CD5-Rg) in the presence 
of selected mAbs that bind well to the surface of TE cells. 
t =  100  x  [AFL(experimental  mAb)-  AFL(P3)]/AFL(P3). 
S =  100  x  [AFL(P3) -  AFL(experimental  mAb)]/AFL(P3). 
Rg (27).  In flow cytometry assays, both TE and HBL-100 
cells reacted strongly with mAb J4-81  (data not shown). 
mAb J3-119,  reported to react with a second epitope on 
the molecule detected by J4-81 (25), enhanced the binding of 
CD6-Rg to TE cells (Fig. 2) by 48  _+  5% (n  -- 6,p <0.005), 
and to HBL-100 cells by 45  __.  11%  (n  =  3, p  <0.1).  To 
confirm that mAb J3-119 recognized the same protein as mAb 
J4-81, the ability ofmAb J3-119 to block the binding ofbio- 
tinylated  J4-81  to TE cells was tested. Whereas mAb A3D8 
to CD44 (which binds well to the surface of TE cells; 29) 
had no effect on J4-81 binding, both J4-81 and J3-119 mAbs 
inhibited the binding of biotinylated J4-81  (99  and 82%, 
respectively;  data not shown). 
mAbJ4-81  and CD6-Rg Bind lO0-kD TE Cell Proteins that 
Are Identical.  To identify the TE cell surface protein(s) that 
bound to CD6-Rg, we devised a strategy whereby CD6-Rg 
interactions with CD6 ligand(s)  on surface 125I-labeled TE 
cells were stabilized with DTSSP, and CD6-Rg-containing 
complexes  were purified using protein A-Sepharose beads. 
Using this strategy, CD6-Rg specifically  reacted with a 100-kD 
TE cell surface protein (Fig. 3) termed CD6L-100. mAb J4-81 
cross-linked  to  l~SI-labeled TE cells also yielded a  lO0-kD 
protein that migrated with the 100-kD  protein recognized 
by CD6-Rg (Fig. 3). Trypsin digestion studies showed that 
the 100-kD protein identified  by  J4-81 had an identical trypsin 
digestion pattern to the protein identified by CD6-Rg (Fig. 
3), indicating that both proteins were identical. CD6L-100 
was determined to be a glycoprotein as mAb J4-81 immuno- 
precipitated CD6L-100 from extracts of  TE cells metabolically 
labeled  with [3H]glucosamine (data not shown). 
The lO0-kD CD6 Ligand is a Divalent Cation-independent 
Ligandfor CD6.  CD6-Rg was able to immunoprecipitate 
CD6L-100  in the presence  and absence of divalent cations, 
suggesting that CD6L-100 may be a divalent cation-indepen- 
dent CD6 ligand. Further, J4-81 only partially inhibited the 
binding of CD6-P,.g  to TE cells in the presence of divalent 
cations.  Thus, there may be more than one ligand for CD6. 
mAb J4-81 almost completely inhibited (80  _+  10% inhibi- 
tion, p <0.1) CD6-R.g binding to TE cells in the presence 
of EDTA (Fig.  2),  confirming that it is primarily involved 
in divalent cation-independent  CD6-CD6 ligand interactions. 
In contrast, mAb J3-119 enhanced CD6-R.g binding by 47 
_  7% (p <0.1) in the absence of divalent cations (Fig.  2). 
Tissue Distribution of mAbJ4-81 Reactivity.  The tissue dis- 
tribution of CD6L-100 was examined on frozen sections of 
a variety of human tissues by indirect IF (Table 2). The reac- 
tivity of mAb J4-81 with human tissues was broad. Whereas 
CD6 was expressed on thymocytes  in postnatal human thymus, 
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Figure 2.  Effect  of  preincubation  ofJ4-81 and  J3-119 on CD6-Kg  binding 
to TE cells. Shown are histograms  of CD6-Rg binding to the surface  of 
human TE cells, as detected  by indirect IF and flow cytometry,  in the 
presence of mAbs P3 (control),  J4-81, or J3-119 in media  containing  diva- 
lent cations (-  EDTA) or no divalent cations (+ EDTA). The binding 
of control human IgG is shown  in each panel. The bottom panels show 
composite summary  histograms of CD6-Rg binding in the presence of 
either P3, J4-81, or J3-119. Data are representative of 10 experiments  in 
the presence  of  divalent  cations  and 2 experiments  with no divalent  cations. 
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and Hassall's bodies (Fig.  4).  In tissues other than  thymus, 
J4-81 reacted with epidermal keratinocytes, gut epithelium, 
breast epithelium, pancreatic acinar cells, pancreatic  islet cells, 
hepatocytes, renal  tubular epithelium,  neurons  of the cere- 
bral  cortex,  and  fibroblasts. 
Figure  3.  mAb J4-81 and CD6-Rg bind to the same 100-kD  glycopro- 
tein on the surface  of human TE cells. Shown are autoradiographs of 1251- 
labeled TE cell surface  proteins cross-linked  to either mAh P3 (control), 
mAb  J4-81, hlgG1 (human Fc control), or CD6-Kg. The cross-linked  pro- 
teins were treated with either 2-ME alone (to cleave  the cross-linker) or 
trypsin and 2-ME before  electrophoresis. Both CD6-Kg and mAb J4-81 
bound to 100-kD proteins with identical trypsin digestion patterns. Data 
are representative of two separate experiments. 
Table 2.  Reactivity of mAbJ4-81  in Sections of Normal 
Human Tissues 
Tissue 
(number  tested)  J4-81  Reactivity 
Thymus  (5) 
Spleen (2) 
Lymph node  (1) 
Tonsil  (2) 
Appendix  (1) 
Colon (2) 
Esophagus  (2) 
Breast (2) 
Liver (2) 
Pancreas (2) 
Kidney  (2) 
Skin (2) 
Brain  (2) 
Hassall's bodies,  epithelium,  fibroblasts 
Scattered mononuclear  cells 
Scattered mononuclear  cells 
Pharyngeal  epithelium,  lymphocytes 
Fibroblasts,  lymphoid  cells, epithelium 
Fibroblasts,  epithelium 
Basal epithelium 
Epithelium,  fibroblasts 
Hepatocytes,  Kupfer cells, fibroblasts 
Acinar and islet cells 
Fibroblasts,  subset of tubules,  Bowman's 
capsule 
Perivascular fibroblasts,  epithelium 
Neurons 
The cell types  reacting with mAb J4-81 in each of the tissue types  are listed. 
Discussion 
In this study, we have shown that human thymic epithe- 
lial  cells  and fibroblasts express  a ligand  for CD6,  termed 
CD6I.,100. We have found two mAbs, J4-81 and J3-119,  that 
bind to CD6IA00 and alter the binding of CD6-Rg to TE 
cells.  Cross-linked  immunoprecipitation  experiments  and 
trypsin digestion revealed that the  100-kD molecule bound 
by CD6-Kg  and by J4-81  were identical. 
Whereas  the role of CD6 as an accessory molecule in T 
cell activation is well established (12-15),  its role in T  cell 
development is not clear. Vollger et al. (3) initially suggested 
that  CD6  may be  an  adhesion  molecule  involved  in  TE- 
thymocyte binding as the anti-CD6 mAbs T12 and 12.1 were 
able to partially block the binding of human thymocytes to 
cultured human TE cells.  Identification of the ligand(s) for 
CD6 may provide a better understanding of the role of CD6 
in  T  cell differentiation  and  activation  (16,  20,  27). 
Partial inhibition of CD6-Rg binding to TE cells and thymic 
fibroblasts by EDTA suggested that there may be more than 
one ligand for CD6, or that the CD6 ligand may have different 
states  of activation depending on divalent cations.  Interest- 
ingly, a 31-kD surface molecule was frequently immunopre- 
cipitated along with CD6I~100 from B cells by mAbs J4-81 
and J3-119  (25).  Whereas  we have clearly established that 
CD6bl00 is a divalent cation-independent  ligand for CD6, 
other ligands for CD6 may exist and CD6L-100 may com- 
plex with other proteins that regulate CD6 binding  (Wee, 
S. F., D. D. Patel,  B. F. Haynes, and A. Aruffo, unpublished 
observations). 
CD6bl00 has a broad tissue distribution, with expression 
on a variety of cell types in normal tissues as defined by mAb 
J4-81 (Fig. 4, Table 2). mAb J4-81 was also tested in the blind 
panel of HLDA-V, and was shown to react with the surface 
of the  following  human  cell  types:  CD34  mia and  CD34  hi 
bone marrow cells,  resting  and TNF-activated  human  um- 
bilical vein endothelial  cells,  dermal endothelial  cells,  acti- 
vated peripheral blood B and T  cells,  a variety of B cell and 
T  cell lymphomas,  monocytes,  myeloid leukemias,  thymic 
epithelial cells, epidermal keratinocytes, skin and lung fibro- 
blasts,  and  a variety  of stromal  cell carcinomas  (26).  The 
broad distribution  of CD6bl00 is consistent with the pre- 
vious  report  that  CD6-Rg  binds  to  a  number  of murine 
lymphoid tissues and transformed human cell lines (27). The 
expression of CD6L-100 in normal noninflamed nonlymphoid 
tissues combined with the accessory role of CD6 in T  cell 
activation implies that CD6-CD6L interactions may be func- 
tional in the earliest  stages of T cell activation, before upreg- 
ulation of MHC and adhesion molecules by T cell-liberated 
cytokines. CD6L-100 expression did not change with IFN-',/ 
activation of TE cells (29) or TNF-ot activation of endothelial 
1566  CD6 Ligand on Human Thymic Epithelium Figure  4.  Expression  of CD6Ir  in postnatal human thymus. Shown are photomicrographs (representative  of experiments on five thymuses)  of 
frozen sections of 2-mo-old human thymus stained by indirect IF with mAb J4-81.  (.4) A section of thymus cortex and B shows a section of thymus 
medulla with Hassall's bodies (FIB). The thymic capsule is indicated by dashed lines in A. Thymic epithelial cells (arrows), in both the cortex and 
in and around HB in medulla, reacted with mAb J4-81. Thymocytes  did not react with mAb J4-81. An identical pattern was seen using mAb J3-119 
(not shown), x400. 
cells (26).  CD6-CD6L  interactions  may also be important 
in the nervous system as neurons of the cerebral cortex ex- 
press both  CD6  (10)  and  CD6Ir 
Osorio et al.  (16) have suggested that the ability of CD6 
to enhance antigen-TCK  signaling  could be physiologically 
significant  especially in cases of low levels of antigen  or in 
antigen  interaction  with  TCKs  of low avidity for the  an- 
tigen.  This  theory fits well with  the  recent  findings  that 
whereas CD6-  peripheral  T  cells have normal proliferative 
responses to T cell mitogens (PHA, anti-CD2 mAb, and im- 
mobilized anti-CD3 mAb) and soluble antigen (tetanus toxin) 
plus APC,  CD6-  T  cells  are  less  alloreactive  than  unfrac- 
tionated PB T  cells (19).  Further,  CD6 mAb UMCD6 in- 
hibited the response of cloned T  cells in autologous MLRs 
(20).  Thus,  inhibition  of CD6-CD6 ligand interactions by 
depletion  of CD6 § peripheral  blood T  cells or therapeutic 
use of anti-CD6 mAbs, soluble CD6, anti-CD6 ligand mAbs, 
or soluble CD6 ligands may decrease autoreactivity in specific 
autoimmune  disease  states. 
Finally, we have defined two different epitopes of the CD6L- 
100 molecule using mAbs J4-81 and J3-119. mAb J4-81 in- 
hibited CD6-Kg binding to TE cells whereas J3-119 enhanced 
CD6-Kg binding. These two epitopes may overlap as J3-119 
inhibited the binding ofJ4-81 to TE cells. Alternatively, mAb 
J3-119 inhibition ofJ4-81 binding could also have been due 
to a change in the conformation  of CD6I~100 induced by 
J3-119 binding.  Thus,  the enhanced binding of CD6-Rg in 
the presence of mAb J3-119 suggested that mAb J3-119 may 
either induce or stabilize the active conformation of CD6L- 
100. Similarly, mAb J4-81 may either be directed to the CD6 
binding site or stabilize the inactive conformation of CD6L- 
100. Nucleotide sequence analysis of the gene encoding CD6L- 
100 and functional  studies using mAbs J4-81 and J3-119  in 
assays of cell interactions,  T  cell  autoreactivity,  and T  cell 
responses to specific antigen  should help further  define the 
roles of CD6-CD6 ligand interactions in T cell development 
and  T  cell effector function. 
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